» Articles » PMID: 37546332

Risk Assessment and Antibody Responses to SARS-CoV-2 in Healthcare Workers

Abstract

Background: Preventing infection in healthcare workers (HCWs) is crucial for protecting healthcare systems during the COVID-19 pandemic. Here, we investigated the seroepidemiology of SARS-CoV-2 in HCWs in Norway with low-transmission settings.

Methods: From March 2020, we recruited HCWs at four medical centres. We determined infection by SARS-CoV-2 RT-PCR and serological testing and evaluated the association between infection and exposure variables, comparing our findings with global data in a meta-analysis. Anti-spike IgG antibodies were measured after infection and/or vaccination in a longitudinal cohort until June 2021.

Results: We identified a prevalence of 10.5% (95% confidence interval, CI: 8.8-12.3) in 2020 and an incidence rate of 15.0 cases per 100 person-years (95% CI: 12.5-17.8) among 1,214 HCWs with 848 person-years of follow-up time. Following infection, HCWs ( = 63) mounted durable anti-spike IgG antibodies with a half-life of 4.3 months since their seropositivity. HCWs infected with SARS-CoV-2 in 2020 ( = 46) had higher anti-spike IgG titres than naive HCWs ( = 186) throughout the 5 months after vaccination with BNT162b2 and/or ChAdOx1-S COVID-19 vaccines in 2021. In a meta-analysis including 20 studies, the odds ratio (OR) for SARS-CoV-2 seropositivity was significantly higher with household contact (OR 12.6; 95% CI: 4.5-35.1) and occupational exposure (OR 2.2; 95% CI: 1.4-3.2).

Conclusion: We found high and modest risks of SARS-CoV-2 infection with household and occupational exposure, respectively, in HCWs, suggesting the need to strengthen infection prevention strategies within households and medical centres. Infection generated long-lasting antibodies in most HCWs; therefore, we support delaying COVID-19 vaccination in primed HCWs, prioritising the non-infected high-risk HCWs amid vaccine shortage.

Citing Articles

SARS-CoV-2 infection rates and associated risk factors in healthcare workers: systematic review and meta-analysis.

Bansal A, Trieu M, Eriksson E, Zhou F, McVernon J, Brokstad K Sci Rep. 2025; 15(1):4705.

PMID: 39922967 PMC: 11807171. DOI: 10.1038/s41598-025-89472-5.


Association between social activities and risk of COVID-19 in a cohort of healthcare personnel.

Shoemaker H, Li H, Zhang Y, Mayer J, Rubin M, Haroldsen C Antimicrob Steward Healthc Epidemiol. 2025; 5(1):e29.

PMID: 39911511 PMC: 11795425. DOI: 10.1017/ash.2024.485.


Dynamic changes of neutralizing antibody and memory T cell responses six months post Omicron XBB reinfection.

Zhao X, Li X, Zhang S, Chen J, Zhao W, Wu N Front Immunol. 2024; 15:1477721.

PMID: 39434881 PMC: 11491401. DOI: 10.3389/fimmu.2024.1477721.


Predictors of seropositivity to SARS-CoV-2 among employees at a large urban medical center.

Kupferwasser D, Flores E, Merino P, Tran D, Liu H, Huang Y BMC Public Health. 2024; 24(1):2754.

PMID: 39385221 PMC: 11462861. DOI: 10.1186/s12889-024-20274-6.


From rejection to the Nobel Prize: Karikó and Weissman's pioneering work on mRNA vaccines, and the need for diversity and inclusion in translational immunology.

Bansal A Front Immunol. 2023; 14:1306025.

PMID: 38022662 PMC: 10663363. DOI: 10.3389/fimmu.2023.1306025.

References
1.
Kahlert C, Persi R, Gusewell S, Egger T, Leal-Neto O, Sumer J . Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study. Clin Microbiol Infect. 2021; 27(9):1336-1344. PMC: 8131187. DOI: 10.1016/j.cmi.2021.05.014. View

2.
Goenka M, Shah B, Goenka U, Das S, Afzalpurkar S, Mukherjee M . COVID-19 prevalence among health-care workers of Gastroenterology department: An audit from a tertiary-care hospital in India. JGH Open. 2021; 5(1):56-63. PMC: 7812452. DOI: 10.1002/jgh3.12447. View

3.
Akinbami L, Chan P, Vuong N, Sami S, Lewis D, Sheridan P . Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity among Healthcare Personnel in Hospitals and Nursing Homes, Rhode Island, USA, July-August 2020. Emerg Infect Dis. 2021; 27(3):823-834. PMC: 7920685. DOI: 10.3201/eid2703.204508. View

4.
Cromer D, Juno J, Khoury D, Reynaldi A, Wheatley A, Kent S . Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol. 2021; 21(6):395-404. PMC: 8082486. DOI: 10.1038/s41577-021-00550-x. View

5.
Wajnberg A, Amanat F, Firpo A, Altman D, Bailey M, Mansour M . Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020; 370(6521):1227-1230. PMC: 7810037. DOI: 10.1126/science.abd7728. View